Skip to main content
LLYEli Lilly and CompanyHold5.9·$1415.55
HoldModerate Confidence
Investment thesis

Eli Lilly is a high-quality healthcare franchise with 56% revenue growth, a wide economic moat, and four consecutive double-digit earnings beats, but the stock has effectively reached the analyst consensus price target with only 0.9% headroom remaining — the setup favors accumulation on weakness rather than initiating at current levels.

Thesis pillars

  • Wide Moat Margin Quality→Stable
  • Consistent Earnings Outperformance→Stable
  • Exceptional Revenue Growth Trajectory→Stable
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026, based on the 10-K filed Feb 12, 2026· older than 90 days

Full reasoning →

Open full analysis

Eli Lilly and Company (LLY) Stock Analysis

Temporary headwind edge

Hold(was: Buy (Wait for Entry))GrowthQualityModerate Confidence

Healthcare · Drug Manufacturers - General

Hold if already holding. Not a fresh buy at $1415.55, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.0% away).

Eli Lilly discovers, develops, and markets human pharmaceutical products in a single business segment, with cardiometabolic health products (including Mounjaro, Zepbound, and Jardiance) and oncology (Verzenio) anchoring a portfolio sold in approximately 90 countries. Six... Read more

$1415.55-6.6% A.UpsideScore 5.9/10#3 of 16 Drug Manufacturers - General
QualityF-score7 / 9FCF yield0.74%
IncomeYield0.48%(5y avg 0.75%)Payout21.71%sustainable
Entry $1282.06(support + ATR)Stop $1218.42Analyst target $1321.72(reached)A.R:R -0.6:1
Analyst consensus$1468.57+3.7%29 analysts with price targets
$1415.55price
$1468.57mean
$940
$1700

Hold if already holding. Not a fresh buy at $1415.55, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.0% away). Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $1415.55 vs the analyst target $1321.72: -6.6% upside; No upside left. Score 5.9/10, moderate confidence.

Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.

10-K grounded · weekly refresh

About Eli Lilly and Company

About Eli Lilly and Company

Mounjaro and Zepbound, Eli Lilly's GLP-1/GIP-based incretin medicines for type 2 diabetes and obesity, together generated 56% of total revenues in 2025 — each individually exceeding $3 billion. Combined with Verzenio (breast cancer), Trulicity, Taltz, and Jardiance, the six highest-revenue products represented 82% of 2025 total revenues. Mounjaro and Zepbound carry U.S. compound patent protection through 2036, and products are sold in approximately 90 countries.

Eli Lilly sells prescription medicines through U.S. wholesale distributors — McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc. — each of which accounts for a significant percentage of consolidated revenue; no other single customer exceeds 10%. Net revenue reflects rebates and discounts negotiated with pharmacy benefit managers and health plans; access to anti-obesity medicines faces particular friction because self-insured U.S. employers must generally opt in for obesity coverage, and payers in many international markets do not cover weight-loss indications. A growing share of U.S. sales flows through LillyDirect, the company's direct-to-patient platform launched to reduce formulary dependency. Jardiance and Basaglar are co-developed with Boehringer Ingelheim, while Tyvyt is commercialized in China with Innovent Biologics.

Show full overview

The Inflation Reduction Act's negotiation mechanism targets Lilly's portfolio directly: HHS selected Jardiance as one of the first ten medicines subject to government-set Medicare prices effective 2026, then in January 2026 selected Trulicity and Verzenio with government pricing effective 2028. Trulicity also faces U.S. compound patent expiry and biologics data protection loss in 2027, concentrating erosion risk within a two-year window. The 10-K notes the company expects additional products selected in future years, which would accelerate revenue erosion further.

See also: Healthcare · Drug Manufacturers - General

From Eli Lilly and Company's most recent 10-K filing, extracted June 11, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 11, 2026

Recent Developments — Eli Lilly and Company

Latest item Nov 11, 2026 · Generated 2026-11-18T11:42:28Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Feb 3, 202777d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
High-quality business
Strong growth profile
Risks
Analyst target reached - limited upside remaining
Near 52-week high (4.0% away)
Leverage penalty (D/E 1.2): -0.5

Key Metrics

P/E (TTM)45.9
P/E (Fwd)27.9
Mkt Cap$1.26T
EV/EBITDA28.1
Profit Mgn31.9%
ROE86.0%
Rev Growth38.6%
Beta0.39
Dividend0.48%
Analysts with ratings37

Quality Signals

Piotroski F7/9MoatWideCompounder✓

Options Flow

P/C0.97neutral
IV41%normal

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ev Ebitda
0.0
Ps
0.3
Pe
2.7
Analyst Target
4.0
Forward Pe
4.4
Peg Ratio
5.7
Forward P/E: 27.9xPEG: 1.32

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
2.5
Rsi
5.0
Ma Position
9.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.5<4.5A.R:R -0.6=NEGATIVEInsider activity: OKNo SEC red flagsEARNINGS PROXIMITY 77d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
68 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $1256.10Resistance $1475.25

Price Targets

A.Upside-6.6%
A.R:R-0.6:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeCautious

Risk Alerts

! Target reached (-6.6% upside)
! momentum at 3.5 (below the engine's 4.5 threshold)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
B
4/4 beats
Next Earnings2027-02-03 (77d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is LLY stock a buy right now?

Hold if already holding. Not a fresh buy at $1415.55, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (4.0% away). Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $1415.55 vs the analyst target $1321.72: -6.6% upside; No upside left. Analyst target $1321.72 reached (−6.6%), stop $1218.42 (−16.2%), A.R:R -0.6:1. Score 5.9/10, moderate confidence.

What is the LLY stock price target?

Analyst target $1321.72 reached (−6.6% from $1415.55); no take-profit level is published. Analyst target $1321.72 reached (−6.6%), stop $1218.42 (−16.2%), A.R:R -0.6:1. Stop-loss: $1218.42.

What are the risks of investing in LLY?

Analyst target reached - limited upside remaining; Near 52-week high (4.0% away); Leverage penalty (D/E 1.2): -0.5.

Is LLY overvalued or undervalued?

Eli Lilly and Company trades at a P/E of 45.9 (forward 27.9). TrendMatrix value score: 3.2/10. Verdict: Hold.

What do analysts say about LLY?

37 analysts rate LLY, with a consensus score of 4.1/5. 29 analysts publish price targets averaging $1469.

What does Eli Lilly and Company do?Eli Lilly discovers, develops, and markets human pharmaceutical products in a single business segment, with...

Eli Lilly discovers, develops, and markets human pharmaceutical products in a single business segment, with cardiometabolic health products (including Mounjaro, Zepbound, and Jardiance) and oncology (Verzenio) anchoring a portfolio sold in approximately 90 countries. Six products each generated more than $3 billion in revenue in 2025, collectively representing 82% of total revenues, with GLP-1/GIP medicines Mounjaro and Zepbound alone at 56%.

Related stocks: AZN (AstraZeneca PLC) · NVO (Novo Nordisk A/S) · ABBV (AbbVie Inc.) · AMGN (Amgen Inc.) · JNJ (Johnson & Johnson)
Home › Stocks › LLY

Latest news

Latest News

Finance.yahoo.com49d ago
Tradingview.com49d ago
Seeking Alpha49d ago
Yahoo Finance49d ago
MSN49d ago
Fool.com49d ago
The Motley Fool49d ago
Stocktwits112d ago
Seeking Alpha203d agoEarnings
Investopedia.com203d agoEarnings
Traders Union203d ago
Yahoo Finance203d agoEarnings
StockStory203d agoEarnings
Barchart.com21d agoEarnings
FXEmpire21d agoEarnings
Benzinga21d agoEarnings
Investopedia21d agoEarnings
JournalArta7d ago